Compare INDI & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INDI | ANL |
|---|---|---|
| Founded | 2007 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 750.1M | 611.1M |
| IPO Year | 2021 | 2022 |
| Metric | INDI | ANL |
|---|---|---|
| Price | $4.13 | $10.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $6.25 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 6.3M | 154.9K |
| Earning Date | 05-07-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.95 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $217,394,000.00 | N/A |
| Revenue This Year | $25.54 | $36.02 |
| Revenue Next Year | $38.45 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.33 | N/A |
| 52 Week Low | $2.32 | $0.88 |
| 52 Week High | $6.05 | $17.25 |
| Indicator | INDI | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 49.39 | 49.37 |
| Support Level | $4.03 | $6.92 |
| Resistance Level | $4.77 | $12.32 |
| Average True Range (ATR) | 0.40 | 1.40 |
| MACD | 0.06 | 0.09 |
| Stochastic Oscillator | 51.36 | 64.88 |
Indie Semiconductor Inc caters to the autotech industry with semiconductors, photonics, and software platforms. The company's products include devices for a multitude of automotive applications spanning vision and radar processors, in-cabin wireless charging and USB power delivery, device interfacing through Apple CarPlay and Android Auto, and high-speed video and data connectivity. New products under evaluation or development include LiDAR, cybersecurity-enabled microcontrollers, and sensor-fusion processors. Its Photonics division mainly offers low-noise lasers, standard, and custom light sources. Geographically, the company generates the majority of its revenue from Greater China and the rest from the United States, Europe, South Korea, and other regions.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.